Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 17

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

What was the disease status? (at diagnosis)

Chronic phase Accelerated phase Blast phase

2

Specify the chronic phase risk score used (at diagnosis)

EUTOS Hasford Sokal Other Unknown

3

Specify the EUTOS score:4

Specify the Hasford score:5

Specify the Sokal score:6

Specify other chronic phase score:7

Specify other chronic phase risk score used:8

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

9

Specify the criteria used to establish accelerated phase or blast phase10

World Health Organization (WHO)

International Bone Marrow Transplant Registry (IBMTR)

Sokal

MD Anderson

European Leukemia Net

Other

Unknown

Specify other criteria:11

Specify the spleen size:12 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

13

Central nervous system

yes no

14

Granulocytic sarcoma

Yes No

15

Other site

yes no

16

Specify other site:17

Laboratory Studies at Diagnosis Questions: 18 - 83

WBC

Known Unknown

18

19 x 109/L (x 103/mm3)

x 106/L

Date sample collected:20 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

21

22 g/dL g/L mmol/L

Date sample collected:23 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

24

Platelets

Known Unknown

25

26 x 109/L (x 103/mm3)

x 106/L

Date sample collected:27 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

28

Eosinophils

Known Unknown

29

30 %

Date sample collected:31 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

32

33 %

Date sample collected:34 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

35

36 %

Date sample collected:37 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

38

39 %

Date sample collected:40 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

41

Were cytogenetics tested via karyotyping?

Yes No Unknown

42

Date sample collected:43 __ __ __ __ - __ __- __ __

Results of tests44

Abnormalities identified

No evaluable metaphases

No abnormalities

45 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

46

Specify other abnormality:47

Was documentation submitted to the CIBMTR?

Yes No

48

Were cytogenetics tested via FISH?

yes no Unknown

49

Date sample collected:50 __ __ __ __ - __ __- __ __

Results of tests51

Abnormalities identified

No evaluable metaphases

No abnormalities

52 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

53

Specify other abnormality:54

Was documentation submitted to the CIBMTR?

Yes No

55

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

56

Date sample collected:57 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

58

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

59

Specify other breakpoint:60

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

61

T315I

Positive Negative Not done

62

WT

Positive Negative Not done

63

L248V

Positive Negative Not done

64

G250E

Positive Negative Not done

65

Q252H

Positive Negative Not done

66

Y253F

Positive Negative Not done

67

E255K

Positive Negative Not done

68

E255V

Positive Negative Not done

69

D276G

Positive Negative Not done

70

E279K

Positive Negative Not done

71

V299L

Positive Negative Not done

72

F317L

Positive Negative Not done

73

M351T

Positive Negative Not done

74

F359V

Positive Negative Not done

75

L384M

Positive Negative Not done

76

H396P

Positive Negative Not done

77

H396R

Positive Negative Not done

78

G398R

Positive Negative Not done

79

F486S

Positive Negative Not done

80

Other mutation

Positive Negative Not done

81

Specify other mutation:82

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

83

Pre-HCT or Pre-Infusion Therapy Questions: 84 - 185

Was therapy given?

yes no

84

Line of Therapy (1) Questions: 85 - 185

Systemic therapy

yes no

85

Date therapy started

Known Unknown

86

Date started:87 __ __ __ __ - __ __- __ __

Was therapy stopped?

Yes No

88

Date therapy stopped

Known Unknown

89

Date stopped:90 __ __ __ __ - __ __- __ __

Specify reason therapy stopped

Toxicity Not tolerable Lack of response Disease progression Other Unknown

91

Specify other reason:92

Bosutinib (Bosulif)

Yes No

93

Busulfan (Busulfex, Myleran)

Yes No

94

Corticosteroids

yes no

95

Cyclophosphamide (Cytoxan)

yes no

96

Cytarabine (Ara-C)

yes no

97

Dasatinib (Sprycel)

yes no

98

Daunorubicin (Cerubidine)

yes no

99

Doxorubicin (Adriamycin)

yes no

100

Homoharringtonine (HHT)

Yes No

101

Hydroxyurea (Droxia, Hydrea)

yes no

102

Idarubicin (Idamycin)

yes no

103

Imatinib (Gleevec)

yes no

104

Interferon­α (Intron, Roferon) (includes PEG)

yes no

105

Methotrexate (MTX) (Amethopterin)

yes no

106

Nilotinib (AMN107, Tasigna)

yes no

107

Ponatinib (Iclusig)

Yes No

108

Vincristine (VCR, Oncovin)

yes no

109

Other systemic therapy

yes no

110

Specify other systemic therapy:111

Radiation therapy

yes no

112

Date therapy started

Known Unknown

113

Date started:114 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

115

Date stopped:116 __ __ __ __ - __ __- __ __

Spleen

yes no

117

Other site(s)

yes no

118

Specify other site(s):119

Splenectomy

yes no

120

Other therapy

yes no

121

Specify other therapy:122

WBC

Known Unknown

123

124 x 109/L (x 103/mm3)

x 106/L

Date sample collected:125 __ __ __ __ - __ __- __ __

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

126

Basophils

Known Unknown

127

128 %

Platelets

Known Unknown

129

130 x 109/L (x 103/mm3)

x 106/L

Date sample collected:131 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

132

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

133

Were cytogenetics tested via karyotyping?

Yes No Unknown

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Results of tests136

Abnormalities identified

No evaluable metaphases

No abnormalities

137 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

138

Specify other abnormality:139

Was documentation submitted to the CIBMTR?

Yes No

140

Were cytogenetics tested via FISH?

yes no Unknown

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Results of tests143

Abnormalities identified

No evaluable metaphases

No abnormalities

144 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

145

Specify other abnormality:146

Was documentation submitted to the CIBMTR?

Yes No

147

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

148

Date sample collected:149 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

150

Specify level of detection151

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

152

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

153

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

154

Specify other breakpoint:155

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

156

T315I

Positive Negative Not done

157

WT

Positive Negative Not done

158

L248V

Positive Negative Not done

159

G250E

Positive Negative Not done

160

Q252H

Positive Negative Not done

161

Y253F

Positive Negative Not done

162

E255K

Positive Negative Not done

163

E255V

Positive Negative Not done

164

D276G

Positive Negative Not done

165

E279K

Positive Negative Not done

166

V299L

Positive Negative Not done

167

F317L

Positive Negative Not done

168

M351T

Positive Negative Not done

169

F359V

Positive Negative Not done

170

L384M

Positive Negative Not done

171

H396P

Positive Negative Not done

172

H396R

Positive Negative Not done

173

G398R

Positive Negative Not done

174

F486S

Positive Negative Not done

175

Other mutation

Positive Negative Not done

176

Specify other mutation:177

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

178

Specify the spleen size:179 centimeters below left lower costal margin

Best response to line of therapy180

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of best response181

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

182

Date assessed:183 __ __ __ __ - __ __- __ __

Did disease relapse/progress following this line of therapy?

yes no

184

Date of relapse/progression:185 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 186 - 191

Specify the spleen size:186 centimeters below left lower costal margin

Was extramedullary disease present?

yes no Unknown

187

Central nervous system

yes no

188

Granulocytic sarcoma

Yes No

189

Other site

yes no

190

Specify other site:191

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 252

Were immature cells (i.e., myelocytes, promyelocytes or myeloblasts) noted on the WBC differential from the peripheral blood?

Yes No Unknown

192

Eosinophils

Known Unknown

193

194 %

Date sample collected:195 __ __ __ __ - __ __- __ __

Basophils

Known Unknown

196

197 %

Date sample collected:198 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

199

200 %

Date sample collected:201 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

202

203 %

Date sample collected:204 __ __ __ __ - __ __- __ __

What was the status of bone marrow fibrosis prior to the preparative regimen / infusion?

Absent Mild Moderate Severe Unknown

205

Date sample collected:206 __ __ __ __ - __ __- __ __

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

207

Were cytogenetics tested via karyotyping?

Yes No Unknown

208

Date sample collected:209 __ __ __ __ - __ __- __ __

Results of tests210

Abnormalities identified

No evaluable metaphases

No abnormalities

211 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

212

Specify other abnormality:213

Was documentation submitted to the CIBMTR?

Yes No

214

Were cytogenetics tested via FISH?

yes no Unknown

215

Date sample collected:216 __ __ __ __ - __ __- __ __

Results of tests217

Abnormalities identified

No evaluable metaphases

No abnormalities

218 % Ph+ metaphases (t(9;22)(q34;q11) and variants)

Other abnormality

yes no

219

Specify other abnormality:220

Was documentation submitted to the CIBMTR?

Yes No

221

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

222

Date sample collected:223 __ __ __ __ - __ __- __ __

Was BCR / ABL detected?

Yes No

224

Specify level of detection225

≤ 0.1 %

> 0.1 %

≥ 3­log reduction from standardized baseline

< 3-log reduction from standardized baseline

Was BCR/ABL level of detection reported on the standardized International Scale (IS)?

Yes No

226

Were 2 consecutive tests performed? (quantitative and/or nested; of adequate quality [sensitivity > 104])

Yes No

227

Specify BCR / ABL breakpoint

p190 p210 p230 Other breakpoint Unknown

228

Specify other breakpoint:229

Was BCR / ABL kinase domain mutation analysis performed?

Yes No Unknown

230

T315I

Positive Negative Not done

231

WT

Positive Negative Not done

232

L248V

Positive Negative Not done

233

G250E

Positive Negative Not done

234

Q252H

Positive Negative Not done

235

Y253F

Positive Negative Not done

236

E255K

Positive Negative Not done

237

E255V

Positive Negative Not done

238

D276G

Positive Negative Not done

239

E279K

Positive Negative Not done

240

V299L

Positive Negative Not done

241

F317L

Positive Negative Not done

242

M351T

Positive Negative Not done

243

F359V

Positive Negative Not done

244

L384M

Positive Negative Not done

245

H396P

Positive Negative Not done

246

H396R

Positive Negative Not done

247

G398R

Positive Negative Not done

248

F486S

Positive Negative Not done

249

Other mutation

Positive Negative Not done

250

Specify other mutation:251

Was documentation submitted to the CIBMTR? (e.g. pathology report)

Yes No

252

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 253 - 256

What was the disease status?253

Complete hematologic response (CHR)

Chronic phase

Accelerated phase

Blast phase

Specify level of response254

No cytogenetic response (No CyR)

Minimal cytogenetic response

Minor cytogenetic response

Partial cytogenetic response (PCyR)

Complete cytogenetic response (CCyR)

Major molecular remission (MMR)

Complete molecular remission (CMR)

Specify blast phase phenotype

Lymphoid Myeloid Mixed phenotype Unknown

255

Date assessed:256 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

In the treating provider's opinion, specify the risk score:

Specify site(s) of disease:

Report findings prior to any first treatment for CML:

Specify cytogenetic abnormalities identified at diagnosis:

Specify cytogenetic abnormalities identified at diagnosis:

Specify site(s) of radiation therapy:

Therapy response:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify cytogenetic abnormalities identified following this line of therapy:

Specify site(s) of disease:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Specify cytogenetic abnormalities identified at last evaluation prior to preparative regimen / infusion:

Center: CRID: 

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

CIBMTR Form 2012 revision 3.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 10